Earnings summaries and quarterly performance for MBX Biosciences.
Executive leadership at MBX Biosciences.
Board of directors at MBX Biosciences.
Research analysts covering MBX Biosciences.
Recent press releases and 8-K filings for MBX.
MBX Biosciences Provides Updates on Clinical Pipeline and Financial Position
MBX
New Projects/Investments
Guidance Update
- MBX Biosciences reported strong Phase 2 AVAIL top-line data for MBX 2109 in hypoparathyroidism in September, showing 79% treatment response at six months. The company plans to engage with the FDA and EMA in Q1 for end-of-phase 1 meetings and expects to start a global Phase 3 registration study in Q3.
- The company's GLP-1/GIP agonist, MBX 4291, for obesity, is designed for once-monthly administration with improved tolerability, leveraging its PEP technology. 12-week MAD data from its Phase 1 study is on track to read out in Q4 2026.
- MBX Biosciences also has MBX 1416 for post-bariatric hypoglycemia, a condition with over 125,000 prevalence in the U.S. and no approved pharmacotherapy. Phase 2A data for this program is expected in Q2 2026.
- MBX Biosciences is in a strong financial position, having raised approximately $200 million in gross proceeds last September, providing cash to support operations into 2029. This funding covers the full completion of the Phase 3 registration study for MBX 2109 and pre-commercial activities.
4 days ago
MBX Biosciences Provides Updates on Clinical Programs and Financial Outlook
MBX
New Projects/Investments
Guidance Update
- MBX Biosciences reported strong Phase II AVAIL top-line data for canvuparatide (MBX 2109) in hypoparathyroidism, showing a 63% response rate at 12 weeks and 79% at 6 months in the open-label extension. The company plans to engage with the FDA and EMA in Q1 2026 and aims to start a global Phase III study in Q3 2026.
- The company is developing MBX 4291, a GLP-1/GIP agonist for obesity, designed for a once-monthly product profile with improved tolerability using its PEP technology. 12-week MAD data is anticipated in Q4 2026.
- MBX Biosciences also has MBX 1416 for post-bariatric hypoglycemia, with Phase IIa data expected in Q2 2026.
- The company is in a strong financial position, with a cash runway into 2029 following a $200 million raise in September, supporting all current clinical programs.
4 days ago
MBX Biosciences Provides Updates on Clinical Programs and Financial Position
MBX
New Projects/Investments
Guidance Update
Product Launch
- MBX Biosciences reported strong Phase 2 AVAIL top-line data for once-weekly canbuparatide in hypoparathyroidism, showing 63% response at 12 weeks and 79% in the open-label extension. The company plans to start a global Phase 3 registration study in Q3 2026 after Q1 2026 regulatory meetings.
- Physicians surveyed indicated they would consider MBX's canbuparatide profile as best-in-class, with 94% of AVAIL patients opting into a two-year open-label extension. One-year open-label extension data is expected in Q2 2026.
- The company's GLP-1/GIP agonist, MBX 4291 for obesity, is being developed as a once-monthly product with 12-week MAD data anticipated in Q4 2026.
- MBX 1416, targeting post-bariatric hypoglycemia, has Phase 2A data expected in Q2 2026 from a 39-day study in 10 adult patients.
- MBX Biosciences is in a strong financial position, having raised approximately $200 million last September, providing cash to support operations into 2029 and fund pivotal programs.
4 days ago
MBX Biosciences Provides Pipeline Update, Highlights Obesity Program
MBX
New Projects/Investments
Revenue Acceleration/Inflection
- MBX Biosciences is advancing three clinical-stage programs in endocrine and metabolic disease, utilizing its Precision Endocrine Peptide (PEP) platform technology.
- The company's obesity candidate, MBX 4291, a potential once-monthly GLP-1 GIP co-agonist prodrug, is expected to release 12-week MAD results in the target population in Q4 2026, with a focus on achieving better tolerability.
- MBX has funding secured into 2029 and anticipates a catalyst-rich year in 2026, including end of Phase 2 meetings for canvuparatide in Q1 2026 and Phase 3 initiation in Q3 2026.
- Their once-weekly PTH replacement therapy, canvuparatide, achieved 79% positive results in its open-label extension and is positioned as a best-in-class treatment for hypoparathyroidism.
Nov 24, 2025, 3:00 PM
MBX Biosciences Outlines Key Clinical Milestones for 2026 and Funding into 2029
MBX
New Projects/Investments
Guidance Update
- MBX Biosciences anticipates a catalyst-rich year in 2026 with key milestones across its three clinical-stage programs in endocrine and metabolic diseases.
- For its once-weekly canvuparatide program in hypoparathyroidism, MBX expects end of Phase II meetings with the FDA and EMA in Q1 2026, followed by the presentation of Avail Phase II results and one-year follow-up data in Q2 2026, and the initiation of a Phase III registration study in Q3 2026. The program reported a 79% responder rate in Phase II.
- The company's potential once-monthly obesity candidate, MBX 4291, a GLP-1/GIP co-agonist prodrug, is expected to release 12-week Multiple Ascending Dose (MAD) results in the target population in Q4 2026. Non-human primate studies demonstrated nearly 20% weight lowering after four once-weekly doses.
- MBX Biosciences has funding secured into 2029, which is intended to support these upcoming catalysts, including Phase III completion and pre-commercial activities for its hypoparathyroidism program.
Nov 24, 2025, 3:00 PM
MBX Biosciences Provides 2026 Catalyst Outlook and Funding Update
MBX
New Projects/Investments
Guidance Update
- MBX Biosciences is advancing three clinical-stage programs, with outstanding phase two top-line results reported in September for its once-weekly canvuparatide, a potential PTH replacement therapy for hypoparathyroidism.
- The company anticipates significant catalysts in 2026, including end-of-phase two meetings with the FDA and EMA for canvuparatide in Q1 2026, and top-line results for its obesity and post-bariatric hypoglycemia (PBH) candidates in Q2 2026.
- MBX Biosciences reported $392 million in cash and equivalents at the end of the last quarter, providing funding to support operations into 2029, which includes completing the phase three study for canvuparatide and pre-commercial activities.
Nov 19, 2025, 4:00 PM
MBX Biosciences Outlines Pipeline Progress, 2026 Catalysts, and Financial Runway
MBX
New Projects/Investments
Guidance Update
- MBX Biosciences is advancing three clinical-stage programs: once-weekly canvuparatide for hypoparathyroidism (HP), a once-monthly GLP-1 GIP co-agonist prodrug for obesity, and a once-weekly MBX peptide for post-bariatric hypoglycemia (PBH).
- The company reported outstanding Phase II top-line results for its once-weekly canvuparatide in September and anticipates end-of-Phase II meetings with the FDA and EMA in Q1 2026, followed by additional one-year follow-up data in Q2 2026.
- Key catalysts in Q2 2026 include top-line results for the 12-week proof-of-concept study of its once-monthly GLP-1 GIP co-agonist prodrug for obesity and top-line results from the Phase IIA proof-of-concept study for its once-weekly MBX peptide for PBH.
- MBX Biosciences ended the last quarter with $392 million in cash and equivalents, providing funding to support operations into 2029, which includes the completion of the Phase III study for HP and pre-commercial activities.
Nov 19, 2025, 4:00 PM
MBX Biosciences Highlights 2026 Clinical Catalysts and Strong Financial Position
MBX
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- MBX Biosciences is focused on becoming a global leader in endocrine and metabolic disorders, utilizing its precision endocrine peptide (PEP) technology to develop differentiated peptide therapeutics.
- The company anticipates significant clinical milestones in 2026 across its three programs: once-weekly canvuparatide for hypoparathyroidism (end-of-phase two meetings with FDA/EMA in Q1 2026, additional data and Phase 3 study initiation in Q2 2026), a once-monthly GLP-1 GIP co-agonist prodrug for obesity (top-line results from a 12-week proof-of-concept study), and a once-weekly MBX peptide for post-bariatric hypoglycemia (top-line results from a Phase 2A proof-of-concept study in Q2 2026).
- MBX reported $392 million in cash and equivalents at the end of the last quarter, providing funding that supports operations into 2029, including the completion of the Phase 3 study for canvuparatide and pre-commercial activities.
Nov 19, 2025, 4:00 PM
MBX Biosciences Outlines 2026 Clinical Catalysts and Pipeline Progress
MBX
New Projects/Investments
Guidance Update
- MBX Biosciences is in a strong financial position with cash into 2029 following a September follow-on raise.
- The company anticipates a catalyst-rich year in 2026 across its three clinical-stage programs.
- For hypoparathyroidism, Canvuparatide demonstrated a 63% responder rate at 12 weeks and 79% at six months in its Phase 2 AVAIL study, with a Phase 3 global registration study planned for Q3 2026.
- In obesity, MBX 4291, a once-monthly GLP-1/GIP co-agonist prodrug, is expected to release 12-week data in Q4 2026, aiming for once-monthly dosing with better tolerability.
- Emmapextide for post-bariatric hypoglycemia (PBH), a condition with no approved pharmacotherapy and over 125,000 US prevalence, will have Phase 2A proof-of-concept study results in Q2 2026.
Nov 12, 2025, 8:20 PM
MBX Biosciences Provides Pipeline Updates and Financial Outlook at Healthcare Innovation Conference
MBX
New Projects/Investments
Guidance Update
- MBX Biosciences reported $392 million in cash and equivalents at the close of the last quarter, following a recent $200 million financing, which is expected to fund operations into 2029.
- The company's lead program, Canvu paratide for hypoparathyroidism, demonstrated a 79% response rate in the open label extension of its phase two study, with 94% of patients willing to continue in the study. Regulatory meetings with the FDA and EMA are scheduled for Q1 2026, with phase three study initiation planned for Q3 2026.
- MBX 4291, an obesity candidate designed for once-monthly dosing, is anticipated to have a 12-week readout in Q4 2026.
- Imipexatide, for Post-Bariatric Hypoglycemia (PBH), showed a 90-hour half-life in Phase 1, supporting once-weekly administration, and is advancing to a Phase 2A proof-of-concept study.
Nov 10, 2025, 8:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more